Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS

Reuters10-21

Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances RECAST Trial Testing <a href="https://laohu8.com/S/Z">$(Z)$</a>-Endoxifen for DCIS

Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577827161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577827161","market":"us","top_or_hot":-1,"title":"Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances RECAST Trial Testing <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-Endoxifen for DCIS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-21 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances RECAST Trial Testing <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-Endoxifen for DCIS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL4wWWy4:1","article_id":"2577827161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577827161","pubTimestamp":1761048057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atossa Therapeutics Inc. has announced progress in the RECAST platform trial, which is focused on ductal carcinoma in situ , a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of -Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATOS":"Atossa Genetics Inc"},"translate_title":"Atossa Therapeutics推进RECAST试验测试(Z)-Endoxifen治疗DCIS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9},"content_text":"Atossa Therapeutics Advances RECAST Trial Testing $(Z)$-Endoxifen for DCIS\n    \n\n        Atossa Therapeutics Inc. has announced progress in the RECAST™ platform trial, which is focused on ductal carcinoma in situ (DCIS), a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST™, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02056) on October 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577827161","isCrawlerRequest":true}